Loading search results
Extracorporeal Membrane Oxygenation Support for Middle East Respiratory Syndrome Induced Respiratory Failure
Sponsor study identifier
interventional
35
1 country
1
Study Start
September 2012
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
June 2015
Actual (reported)Study Completion
October 2015
Actual (reported)A highly pathogenic human coronavirus causing respiratory disease emerged in Saudi Arabia in 2012. This viral infection termed Middle East respiratory syndrome coronavirus (MERS-CoV) is associated with high mortality rate in approximately 36% of reported patients. The World Health Organization (WHO) reported 1,374 laboratory-confirmed worldwide infections, including at least 490 related deaths, from September, 2012, to July 24, 2015.2 The higher incidence of MERS-CoV infections in Saudi Arabia may be related to multiple factors, including seasonality, increased proactive screening, poor infection control measures, low relative humidity, and high temperature. Infected patients with MERS-CoV usually have abnormal findings on chest radiography, ranging from subtle to extensive unilateral and bilateral abnormalities. MERS progresses rapidly to respiratory failure, in approximately 2/3 of infected patients, which has a high mortality rate, particularly in immunocompromised patients. Extracorporeal membrane oxygenation (ECMO) has emerged as a rescue therapy in patients with refractory hypoxemia during the H1N1 epidemic.The use of veno-venous (VV)-ECMO provides respiratory support for patients with respiratory failure, whereas the use of veno-arterial (VA)-ECMO could be helpful in those with cardiorespiratory failure.10 However, the survival rate of the infected patients with H1N1 who required the use of ECMO varies considerably among the Caucasian and Asian countries (90% survival in Sweden and 83% in the UK13 vs. 35% in Japan). This large discrepancy could be explained with lack of satisfactory equipment, therapeutic guidelines, training of staff, and effective systems allowing patient transfer to the dedicated ECMO centres. Guery and co-investigators described the use of ECMO in two French patients with cardiorespiratory failure secondary to MERS-CoV infection.This has been extended for treatment of refractory hypoxemic respiratory failure during the Saudi MERS-CoV outbreak.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
October 2015
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
September 2012
Date type not reportedThis date has not been verified as actual or estimated.
June 2015
Actual (reported)October 2015
Actual (reported)December 4, 2015
Actual (reported)December 10, 2015
Actual (reported)Mortality rate
In-hospital mortality
For 2 months after admission to hospital
Use of antiviral medications
For 2 months after admission to hospital
Use of steroid medications
For 2 months after admission to hospital
Use of interferons
For 2 months after admission to hospital
Use of immunoglobulin
For 2 months after admission to hospital
Use of vasopressor medications
For 2 months after admission to hospital
Number of participants with diabetes milletus on blood glucose test
For 1 month before admission to hospital
Number of participants with pregnancy on pregnancy test
For 9 months before admission to hospital
Number of participants with hypertension on blood pressure recordings
For 1 month before admission to hospital
Patients received Extracorporeal Membrane Oxygenation (ECMO) support
Patients did not receive Extracorporeal Membrane Oxygenation (ECMO) support
Patients received veno-venous Extracorporeal Membrane Oxygenation (ECMO) support
Patients received no Extracorporeal Membrane Oxygenation (ECMO) support
Dammam University KFHU
Khobar, EP, 31952, Saudi Arabia
Anees Sindi, FRCPC
King Abdulaziz University, Jeddah, Saudi Arabia
Muhammed S Alshahrani, FRCPC
University of Dammam, Dammam, Saudi Arabia
35 participants (actual enrollment reported by the registry).
First Submitted
December 4, 2015
First Posted
December 10, 2015
Study Start
September 2012
Date type not reportedThis date has not been verified as actual or estimated.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Contact the study team to confirm eligibility.
Primary Completion
June 2015
Actual (reported)Study Completion
October 2015
Actual (reported)Last Updated
December 10, 2015
Record last verified: 2015-12
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: